Breaching peripheral tolerance promotes the production of HIV-1–neutralizing antibodies

A subset of characterized HIV-1 broadly neutralizing antibodies (bnAbs) are polyreactive with additional specificities for self-antigens and it has been proposed immunological tolerance may present a barrier to their participation in protective humoral immunity. We address this hypothesis by immunizing autoimmune-prone mice with HIV-1 Envelope (Env) and characterizing the primary antibody response for HIV-1 neutralization. We find autoimmune mice generate neutralizing antibody responses to tier 2 HIV-1 strains with alum treatment alone in the absence of Env. Importantly, experimentally breaching immunological tolerance in wild-type mice also leads to the production of tier 2 HIV-1–neutralizing antibodies, which increase in breadth and potency following Env immunization. In both genetically prone and experimentally induced mouse models of autoimmunity, increased serum levels of IgM anti-histone H2A autoantibodies significantly correlated with tier 2 HIV-1 neutralization, and anti-H2A antibody clones were found to neutralize HIV-1. These data demonstrate that breaching peripheral tolerance permits a cross-reactive HIV-1 autoantibody response able to neutralize HIV-1.

[1]  B. Haynes,et al.  Role of immune mechanisms in induction of HIV-1 broadly neutralizing antibodies. , 2011, Current opinion in immunology.

[2]  M. Nussenzweig,et al.  Predominant Autoantibody Production by Early Human B Cell Precursors , 2003, Science.

[3]  A. Feeney,et al.  Repertoire-based selection into the marginal zone compartment during B cell development , 2008, The Journal of experimental medicine.

[4]  B. Chesebro,et al.  Apobec3 Encodes Rfv3, a Gene Influencing Neutralizing Antibody Control of Retrovirus Infection , 2008, Science.

[5]  Pham Phung,et al.  Broad and Potent Neutralizing Antibodies from an African Donor Reveal a New HIV-1 Vaccine Target , 2009, Science.

[6]  D. Burton,et al.  Immune Tolerance Negatively Regulates B Cells in Knock-In Mice Expressing Broadly Neutralizing HIV Antibody 4E10 , 2013, The Journal of Immunology.

[7]  M. Satoh,et al.  Widespread susceptibility among inbred mouse strains to the induction of lupus autoantibodies by pristane , 2000, Clinical and experimental immunology.

[8]  R. Palacios,et al.  Human immunodeficiency virus infection and systemic lupus erythematosus. An unusual case and a review of the literature , 2002, Lupus.

[9]  William C. Olson,et al.  Evaluating the Immunogenicity of a Disulfide-Stabilized, Cleaved, Trimeric Form of the Envelope Glycoprotein Complex of Human Immunodeficiency Virus Type 1 , 2005, Journal of Virology.

[10]  Ron Diskin,et al.  Sequence and Structural Convergence of Broad and Potent HIV Antibodies That Mimic CD4 Binding , 2011, Science.

[11]  R. Perlmutter,et al.  Evidence for selection of a population of multi-reactive B cells into the splenic marginal zone. , 1997, International immunology.

[12]  Renate Kunert,et al.  Cardiolipin Polyspecific Autoreactivity in Two Broadly Neutralizing HIV-1 Antibodies , 2005, Science.

[13]  L. Wysocki,et al.  Identification of anergic B cells within a wild-type repertoire. , 2006, Immunity.

[14]  David Nemazee,et al.  Receptor editing in lymphocyte development and central tolerance , 2006, Nature Reviews Immunology.

[15]  John P. Moore,et al.  Murine Antibody Responses to Cleaved Soluble HIV-1 Envelope Trimers Are Highly Restricted in Specificity , 2015, Journal of Virology.

[16]  B. R. Kaye Rheumatologic manifestations of infection with human immunodeficiency virus (HIV). , 1989, Annals of internal medicine.

[17]  L. Stamatatos,et al.  Generation and structural analysis of soluble oligomeric gp140 envelope proteins derived from neutralization-resistant and neutralization-susceptible primary HIV type 1 isolates. , 2000, AIDS research and human retroviruses.

[18]  N. Olsen,et al.  Protein array autoantibody profiles for insights into systemic lupus erythematosus and incomplete lupus syndromes , 2006, Clinical and experimental immunology.

[19]  Retraction Kiehntopf,et al.  Retraction , 1997, Concurr. Comput. Pract. Exp..

[20]  C. Goodnow,et al.  Clonal redemption of autoantibodies by somatic hypermutation away from self-reactivity during human immunization , 2016, The Journal of experimental medicine.

[21]  R. Pelanda,et al.  Division of labor during primary humoral immunity , 2013, Immunologic research.

[22]  J. Moore,et al.  Targeting HIV-1 envelope glycoprotein trimers to B cells using APRIL improves antibody responses , 2012, Retrovirology.

[23]  P. Simmonds,et al.  Independent evolution of macrophage-tropism and increased charge between HIV-1 R5 envelopes present in brain and immune tissue , 2012, Retrovirology.

[24]  J. Mascola,et al.  Passive transfer of modest titers of potent and broadly neutralizing anti-HIV monoclonal antibodies block SHIV infection in macaques , 2014, The Journal of experimental medicine.

[25]  G. Debnath,et al.  D-101 HIV-1 neutralizing antibodies induced by native-like envelope trimers , 2016 .

[26]  T. Kepler,et al.  Initiation of immune tolerance–controlled HIV gp41 neutralizing B cell lineages , 2016, Science Translational Medicine.

[27]  J. Binley,et al.  Targeting HIV-1 Envelope Glycoprotein Trimers to B Cells by Using APRIL Improves Antibody Responses , 2011, Journal of Virology.

[28]  L. Stamatatos,et al.  Macrophage tropism of human immunodeficiency virus type 1 and utilization of the CC-CKR5 coreceptor , 1997, Journal of virology.

[29]  B. Haynes,et al.  Polyreactivity and Autoreactivity among HIV-1 Antibodies , 2014, Journal of Virology.

[30]  R. Pelanda,et al.  Dual-reactive B cells are autoreactive and highly enriched in the plasmablast and memory B cell subsets of autoimmune mice , 2012, The Journal of experimental medicine.

[31]  Martin A. Nowak,et al.  Antibody neutralization and escape by HIV-1 , 2003, Nature.

[32]  Robin A. Weiss,et al.  Neutralizing antibodies to HIV-1 induced by immunization , 2013, The Journal of experimental medicine.

[33]  P. Sharp,et al.  Complete nucleotide sequence, genome organization, and biological properties of human immunodeficiency virus type 1 in vivo: evidence for limited defectiveness and complementation , 1992, Journal of virology.

[34]  P. Marrack,et al.  Murine gammaherpesvirus 68 infection protects lupus-prone mice from the development of autoimmunity , 2012, Proceedings of the National Academy of Sciences.

[35]  David Baltimore,et al.  Antibody-based Protection Against HIV Infection by Vectored ImmunoProphylaxis , 2011, Nature.

[36]  H. Liao,et al.  Autoreactivity in an HIV-1 broadly reactive neutralizing antibody variable region heavy chain induces immunologic tolerance , 2009, Proceedings of the National Academy of Sciences.

[37]  J. Mascola,et al.  BLyS-Mediated Modulation of Naive B Cell Subsets Impacts HIV Env-Induced Antibody Responses , 2012, The Journal of Immunology.

[38]  H. Liao,et al.  Induction of HIV-1 Broad Neutralizing Antibodies in 2F5 Knock-in Mice: Selection against Membrane Proximal External Region–Associated Autoreactivity Limits T-Dependent Responses , 2013, The Journal of Immunology.

[39]  D. Klinman Polyclonal B cell activation in lupus-prone mice precedes and predicts the development of autoimmune disease. , 1990, The Journal of clinical investigation.

[40]  J. Kappes,et al.  Molecular characterization of human immunodeficiency virus type 1 cloned directly from uncultured human brain tissue: identification of replication-competent and -defective viral genomes , 1991, Journal of virology.

[41]  Philippa Marrack,et al.  Alum Induces Innate Immune Responses through Macrophage and Mast Cell Sensors, But These Sensors Are Not Required for Alum to Act As an Adjuvant for Specific Immunity1 , 2009, The Journal of Immunology.

[42]  John P. Moore,et al.  Stabilization of the Soluble, Cleaved, Trimeric Form of the Envelope Glycoprotein Complex of Human Immunodeficiency Virus Type 1 , 2002, Journal of Virology.

[43]  M. McCarter,et al.  Mouse marginal zone B cells harbor specificities similar to human broadly neutralizing HIV antibodies , 2013, Proceedings of the National Academy of Sciences.

[44]  N. Olsen,et al.  Risk factors for ANA positivity in healthy persons , 2011, Arthritis Research & Therapy.

[45]  T. Kepler,et al.  An autoreactive antibody from an SLE/HIV-1 individual broadly neutralizes HIV-1. , 2014, The Journal of clinical investigation.

[46]  Holly Janes,et al.  Tiered Categorization of a Diverse Panel of HIV-1 Env Pseudoviruses for Assessment of Neutralizing Antibodies , 2009, Journal of Virology.

[47]  C. Goodnow,et al.  Redemption of autoantibodies on anergic B cells by variable-region glycosylation and mutation away from self-reactivity , 2014, Proceedings of the National Academy of Sciences.

[48]  R. Pelanda,et al.  Receptor editing for better or for worse. , 2006, Current opinion in immunology.

[49]  J. Levine,et al.  Looking at Child Labor , 2002, Science.

[50]  J. D. Capra,et al.  Mature B cells class switched to IgD are autoreactive in healthy individuals. , 2007, The Journal of clinical investigation.

[51]  Florian Klein,et al.  Structural Insights on the Role of Antibodies in HIV-1 Vaccine and Therapy , 2014, Cell.

[52]  Hongmei Gao,et al.  Optimization and validation of the TZM-bl assay for standardized assessments of neutralizing antibodies against HIV-1. , 2014, Journal of immunological methods.

[53]  TA Kion,et al.  Anti-HIV and anti-anti-MHC antibodies in alloimmune and autoimmune mice , 1991, Science.

[54]  S. Gauld,et al.  B-cell anergy: from transgenic models to naturally occurring anergic B cells? , 2007, Nature Reviews Immunology.

[55]  Mario Roederer,et al.  Rational Design of Envelope Identifies Broadly Neutralizing Human Monoclonal Antibodies to HIV-1 , 2010, Science.

[56]  Maxim N. Artyomov,et al.  Polyreactivity increases the apparent affinity of anti-HIV antibodies by heteroligation , 2010, Nature.

[57]  E. Wakeland,et al.  Polygenic control of susceptibility to murine systemic lupus erythematosus. , 1994, Immunity.

[58]  B. Haynes,et al.  Rescue of HIV-1 Broad Neutralizing Antibody-Expressing B Cells in 2F5 VH × VL Knockin Mice Reveals Multiple Tolerance Controls , 2011, The Journal of Immunology.

[59]  Dennis R Burton,et al.  Broadly Neutralizing Antibodies to HIV and Their Role in Vaccine Design. , 2016, Annual review of immunology.

[60]  Y. Shoenfeld,et al.  Autoimmune/inflammatory syndrome induced by adjuvants (Shoenfeld’s syndrome): clinical and immunological spectrum , 2013, Expert review of clinical immunology.

[61]  John P. Moore,et al.  Immunogenicity of Stabilized HIV-1 Envelope Trimers with Reduced Exposure of Non-neutralizing Epitopes , 2015, Cell.

[62]  Kindra M Kelly-Scumpia,et al.  Colocalization of Antigen-Specific B and T Cells within Ectopic Lymphoid Tissue following Immunization with Exogenous Antigen1 , 2008, The Journal of Immunology.

[63]  T. Ross,et al.  C3d enhances immune responses using low doses of DNA expressing the HIV-1 envelope from codon-optimized gene sequences. , 2005, Current HIV research.

[64]  Michael S. Seaman,et al.  Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117 , 2015, Nature.

[65]  B. Korber,et al.  HIV-Host Interactions: Implications for Vaccine Design. , 2016, Cell host & microbe.

[66]  J. Mascola,et al.  Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies , 2000, Nature Medicine.

[67]  A. Coutinho,et al.  Negative selection of multireactive B cell clones in normal adult mice , 1994, European journal of immunology.

[68]  Y. Kuroda,et al.  Distinctive patterns of autoimmune response induced by different types of mineral oil. , 2004, Toxicological sciences : an official journal of the Society of Toxicology.

[69]  R. Palacios,et al.  Human immunodeficiency virus infection and systemic lupus erythematosus , 2004, International journal of STD & AIDS.

[70]  A. Cappione,et al.  Regulation of inherently autoreactive VH4-34 B cells in the maintenance of human B cell tolerance. , 2001, The Journal of clinical investigation.

[71]  S. Akira,et al.  TLR9 and TLR4 are required for the development of autoimmunity and lupus nephritis in pristane nephropathy. , 2010, Journal of autoimmunity.

[72]  M Anthony Moody,et al.  Antibody polyspecificity and neutralization of HIV-1: a hypothesis. , 2006, Human antibodies.

[73]  F. Pereyra,et al.  A method for identification of HIV gp140 binding memory B cells in human blood. , 2009, Journal of immunological methods.

[74]  C. Goodnow,et al.  Cellular and genetic mechanisms of self tolerance and autoimmunity , 2005, Nature.

[75]  N. Olsen,et al.  IgG and IgM autoantibody differences in discoid and systemic lupus patients , 2012, The Journal of investigative dermatology.

[76]  M. Nussenzweig,et al.  Polyreactive antibodies in adaptive immune responses to viruses , 2011, Cellular and Molecular Life Sciences.

[77]  M. Colonna,et al.  Type I IFN enhances follicular B cell contribution to the T cell–independent antibody response , 2010, The Journal of experimental medicine.

[78]  I. McLean,et al.  VACCINE POTENTIATION BY EMULSIFICATION WITH PURE HYDROCARBON COMPOUNDS. , 1963, Journal of immunology.

[79]  J. Kappes,et al.  Emergence of Resistant Human Immunodeficiency Virus Type 1 in Patients Receiving Fusion Inhibitor (T-20) Monotherapy , 2002, Antimicrobial Agents and Chemotherapy.

[80]  Nico Pfeifer,et al.  HIV-1 antibody 3BNC117 suppresses viral rebound in humans during treatment interruption , 2016, Nature.

[81]  J. Sodroski,et al.  Elicitation of Neutralizing Antibodies with DNA Vaccines Expressing Soluble Stabilized Human Immunodeficiency Virus Type 1 Envelope Glycoprotein Trimers Conjugated to C3d , 2004, Journal of Virology.

[82]  D. Wallace,et al.  False-positive human immunodeficiency virus testing in patients with lupus erythematosus. , 1993, Seminars in arthritis and rheumatism.

[83]  M. Satoh,et al.  Induction of lupus-associated autoantibodies in BALB/c mice by intraperitoneal injection of pristane , 1994, The Journal of experimental medicine.

[84]  F. Poccia,et al.  Epitope specificity, antibody-dependent cellular cytotoxicity, and neutralizing activity of antibodies to human immunodeficiency virus type 1 in autoimmune MRL/lpr mice. , 1993, The Journal of infectious diseases.

[85]  M. Nussenzweig,et al.  Memory B Cell Antibodies to HIV-1 gp140 Cloned from Individuals Infected with Clade A and B Viruses , 2011, PloS one.

[86]  John P. Moore,et al.  HIV-1 Envelope Trimer Design and Immunization Strategies To Induce Broadly Neutralizing Antibodies. , 2016, Trends in immunology.

[87]  J. Mascola,et al.  Characterization of Antibody Responses Elicited by Human Immunodeficiency Virus Type 1 Primary Isolate Trimeric and Monomeric Envelope Glycoproteins in Selected Adjuvants , 2006, Journal of Virology.

[88]  S. Akira,et al.  Contribution of Receptor Editing to the Antibody Repertoire , 2007 .

[89]  B. Haynes,et al.  HIV‐1 neutralizing antibodies: understanding nature's pathways , 2013, Immunological reviews.

[90]  N. Letvin,et al.  Report of a false-positive HIV test result and the potential use of additional tests in establishing HIV serostatus. , 2000, Archives of internal medicine.

[91]  A. Riva,et al.  Systemic lupus erythematosus and HIV infection: a whimsical relationship. Reports of two cases and review of the literature , 2013, Clinical Rheumatology.

[92]  T. Kepler,et al.  Identification of autoantigens recognized by the 2F5 and 4E10 broadly neutralizing HIV-1 antibodies , 2013, The Journal of experimental medicine.

[93]  D. Littman,et al.  Fusion-competent vaccines: broad neutralization of primary isolates of HIV. , 1999, Science.

[94]  J. Mascola,et al.  Robust Neutralizing Antibodies Elicited by HIV-1 JRFL Envelope Glycoprotein Trimers in Nonhuman Primates , 2013, Journal of Virology.